COMMUNIQUÉS West-GlobeNewswire

Rakovina Therapeutics Announces Closing of First Tranche, Upsize and Extension of Non-Brokered Private Placement
12/08/2026
Expanded financing broadens Rakovina’s strategic investor base and reinforces confidence in its AI-powered oncology platform VANCOUVER, British Columbia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX [...]
BioPorto A/S to host an investor webcast on the results for the first half of 2026
12/08/2026
BioPorto A/S to host an investor webcast on the results for the first half of 2026 COPENHAGEN, DENMARK, August 12, 2026 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), announced today that CEO [...]
FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares
12/08/2026
FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares AUSTIN, Texas and LYON, France, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (NASDAQ: FOCL) (the “Company”), a global leader in robotic [...]
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
12/08/2026
GRAND CAYMAN, Cayman Islands, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference ( [...]
Anteris Technologies Announces Results for the Second Quarter of 2026
12/08/2026
MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, [...]
COSCIENS Biopharma Inc. Reports Q2 2026 Results
11/08/2026
TORONTO, ONTARIO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCI.F) (“ COSCIENS ” or the “ Company ”) today reported its financial and operating results for the second quarter ended [...]
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
11/08/2026
New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI Strengthened executive team and board to bolster late-stage drug [...]
Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
11/08/2026
Assessing unblinded Phase 3 HERO and OLE data for ARD-101 in PWS in the third quarter of 2026 to support an informed determination of next steps Remains in active discussions with the FDA to support resolution of the [...]
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
11/08/2026
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today [...]
Apollomics Announces $10 Million Private Placement Transaction
11/08/2026
FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to [...]
FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026
11/08/2026
FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026 AUSTIN, Texas, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, [...]
FocalTherics™ Announces Proposed Public Offering of American Depositary Shares
11/08/2026
FocalTherics™ Announces Proposed Public Offering of American Depositary Shares AUSTIN, Texas and LYON, France, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (NASDAQ: FOCL) (the “Company”), a global leader in robotic [...]
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
11/08/2026
Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCRC Following [...]
Sanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited)
11/08/2026
FORT WORTH, TX, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” “Sanara MedTech,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and [...]
LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
11/08/2026
Q2 2026 total revenue of $5.5 million from VIZZ product sales and global license agreements Strong patient persistence, with over 60% of patients in our dominant ePharmacy channel purchasing multiple monthly packs since [...]
Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
11/08/2026
First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results Cash balance of $18.1 million as of June 30, 2026 [...]
Codexis Reports Second Quarter 2026 Financial Results
11/08/2026
Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis® [...]
Spectral AI Announces 2026 Second Quarter Financial Results
11/08/2026
Company Continues to Advance Towards First Commercial Sales of the DeepView ® System for Burn Indication Strong Cash Position of $14.0 Million at June 30, 2026 DALLAS, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc [...]
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
11/08/2026
FORTIFY, a Phase 1b indication expansion trial of PLN-101095, experiencing strong enrollment Appointed seasoned oncology drug development leaders Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of [...]

Pages